MSD K.K. (head office: Chiyoda, Tokyo; President: Jannie Oosthuizen; "MSD") and Kissei Pharmaceutical Co., Ltd. (head office: Matsumoto, Nagano; Chairman and CEO: Mutsuo Kanzawa; "Kissei") announce the decision to transfer the distribution operation of MARIZEV® Tablets 25 mg/12.5 mg (generic name: omarigliptin), a type-2 diabetes treatment that MSD holds the manufacturing and marketing authorization of, to Kissei effective April 2020.
While MSD will continue to hold MARIZEV® manufacturing and marketing authorization, the two companies have agreed that Kissei will eventually take over the authorization. Arrangements will be made accordingly by the two companies.
Released in November 2015 in Japan before other parts of the world, MARIZEV® is a once-weekly sustained selective DPP-4 inhibitor that has been prescribed to many patients with type-2 diabetes. MSD and Kissei will ensure that MARIZEV® will continue to fulfill the needs of patients and healthcare professionals.
For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A., outside of the United States and Canada. Through our prescription medicines, vaccines, biologic therapies and animal health products, we operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more details of MSD, please visit www.msd.co.jp.
With the management philosophy of "contribute to society through high-quality, innovative pharmaceutical products" and "serve society through our employees", Kissei is committed to providing unique new drugs to patients worldwide as a R&D-oriented pharmaceutical company. With focus on core fields such as urology, renal diseases and dialysis, diabetes, gastroenterology, and rare diseases, Kissei manufactures and markets diabetes drugs including GLUFAST, a rapid -acting insulin secretagogue discovered and developed by Kissei, and GLUBES, a fixed-dose combination tablet of the rapid-acting insulin secretagogue and an agent that improves postprandial hyperglycemia.
To read more Press Release articles, click here.